[Future medications for tobacco and cannabis dependence].

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Bulletin de l'Académie Nationale de Médecine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 18663981PMCID PMC2744405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High Reinforcing Efficacy of Nicotine in Non-Human Primates

  2007cited by this paper
• Dopamine D3 receptor ligands for the treatment of tobacco dependence

  2007cited by this paper
• Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats

  2006cited by this paper
• Opioid antagonists for smoking cessation.

  2006cited by this paper
• Nicotine as a typical drug of abuse in experimental animals and humans

  2006cited by this paper
• Opiate antagonists reduce cocaine but not nicotine self-administration

  2005cited by this paper
• The dopamine D3 receptor and drug dependence: effects on reward or beyond?

  2005cited by this paper
• Nicotine-Associated Cues Maintain Nicotine-Seeking Behavior in Rats Several Weeks after Nicotine Withdrawal: Reversal by the Cannabinoid (CB1) Receptor Antagonist, Rimonabant (SR141716)

  2005cited by this paper
• Dopamine D3 Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences through a Mechanism that does not Involve Discriminative-Stimulus or Antidepressant-Like Effects

  2005cited by this paper
• The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

  2005cited by this paper
• A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning

  2005cited by this paper
• Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence

  2005cited by this paper
• Selective dopamine D3 receptor antagonism by SB‐277011A attenuates cocaine reinforcement as assessed by progressive‐ratio and variable‐cost–variable‐payoff fixed‐ratio cocaine self‐administration in rats

  2005cited by this paper
• Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans.

  2005cited by this paper
• Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats

  2005cited by this paper
• Nicotine induces conditioned place preferences over a large range of doses in rats

  2005cited by this paper
• CB1 receptor antagonists for the treatment of nicotine addiction.

  2005cited by this paper
• The opioid antagonist naltrexone reduces the reinforcing effects of Δ9-tetrahydrocannabinol (THC) in squirrel monkeys

  2004cited by this paper
• Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice

  2004cited by this paper
• Role of dopamine D3 receptors in the addictive properties of ethanol.

  2004cited by this paper
• Nicotine maintains robust self-administration in rats on a limited-access schedule

  2004cited by this paper
• Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9-tetrahydrocannabinol.

  2004cited by this paper
• Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats.

  2004cited by this paper
• Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences

  2004cited by this paper
• Selective Antagonism at Dopamine D3 Receptors Prevents Nicotine-Triggered Relapse to Nicotine-Seeking Behavior

  2003cited by this paper
• Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats

  2003cited by this paper
• Disruption of nicotine conditioning by dopamine D3 receptor ligands

  2003cited by this paper
• Attenuation of Cue-Controlled Cocaine-Seeking by a Selective D3 Dopamine Receptor Antagonist SB-277011-A

  2003cited by this paper
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

  2002cited by this paper
• Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

  2002cited by this paper
• SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

  2002cited by this paper
• Role of the dopamine D3 receptor in reactivity to cocaine‐associated cues in mice

  2002cited by this paper
• Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.

  2002cited by this paper
• Second-order schedules of drug self-administration in animals

  2002cited by this paper
• Δ9‐tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect

  2001cited by this paper
• (R)-Methanandamide and Δ9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide

  2001cited by this paper
• Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

  2001cited by this paper
• Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse.

  2001cited by this paper
• Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys

  2000cited by this paper
• Cannabinoid Withdrawal Syndrome Is Reduced in Pre-Proenkephalin Knock-Out Mice

  2000cited by this paper
• Second-order schedules of drug reinforcement in rats and monkeys: measurement of reinforcing efficacy and drug-seeking behaviour

  2000cited by this paper
• Dopamine D3 receptor agents as potential new medications for drug addiction

  2000cited by this paper
• Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist

  1999cited by this paper
• Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.

  1998cited by this paper
• Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

  1997cited by this paper
• Adaptive Increase in D3 Dopamine Receptors in the Brain Reward Circuits of Human Cocaine Fatalities

  1996cited by this paper
• Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

  1990cited by this paper
• Stimulus effects of Δ9-THC and its interaction with naltrexone and catecholamine blockers in rats

  1977cited by this paper

• No citing papers are available for this paper.